Home Stacks Wolverine Stack Dosing Guide: BPC-157 + TB-500 Protocol (2026)
Stack / Research Guide
An evidence-based Wolverine Stack protocol guide covering combined BPC-157 and TB-500 dosing, reconstitution math, timing, cycle length, and safety considerations for this recovery-focused peptide stack.
By Garret GrantFounder & Lead ResearcherLast reviewed June 2026
The Wolverine Stack is a community shorthand for pairing two research peptides — BPC-157 and TB-500 — into one tissue-repair-focused protocol. The name is borrowed from the comic-book character known for fast healing; it is not a clinical designation and not an FDA-approved treatment.
BPC-157 is studied for local tissue effects: angiogenesis at the injury site, growth-factor signaling, and tendon-bone interface healing in animal models. TB-500 is a fragment of Thymosin Beta-4 and is studied for systemic effects: cell migration, anti-inflammatory signaling, and progenitor-cell mobilization. The stack rationale is that the two compounds cover non-overlapping pieces of the same problem.
Two formats dominate research planning: a pre-blended 1:1 vial (most common is 20 mg total, 10 mg of each compound) dosed daily, or two separate vials dosed on different schedules — daily BPC-157 with twice-weekly TB-500 loading. This guide covers both. For unit math, see the PepPal reconstitution calculator.
Compounds
BPC-157 + TB-500, often as a 1:1 pre-blended 20 mg vial.
Schedule
Daily blend draws, or daily BPC-157 + 2x/week TB-500 separate-vial loading.
Reconstitute
2.0 mL BAC water in a 20 mg blend → 10 mg/mL total (5 mg/mL each).
Measuring
On a U-100 syringe, 10 units = 0.10 mL = 1.0 mg total blend.
Cycle
Most community protocols run 6–12 weeks total, often loading + maintenance.
Status
Not FDA-approved. Removed from Category 2 on Apr 22, 2026; PCAC review Jul 23, 2026.
Disclaimer
This page is an educational research reference. It is not medical advice, not a treatment plan, and not a recommendation to use these compounds. Neither BPC-157 nor TB-500 is FDA-approved. Both are prohibited by WADA. Use of unregulated research-chemical peptides carries quality-control and contamination risk, and there is no long-term human safety data for either compound.
This page is for Wolverine Stack steps, timing, and supplies. Want the wider research view? Visit the Wolverine Stack research guide. It covers each peptide, studies, safety notes, and legal status.
Two dosing models dominate Wolverine Stack research planning. The Pre-blended Vial is typically a 1:1 BPC-157 + TB-500 mixture, drawn as a single daily dose. Separate Vials lets BPC-157 and TB-500 run on independent schedules — daily BPC-157 with twice-weekly TB-500 loading. The choice usually comes down to whether independent dose control matters more than convenience.
Evidence boundary
No published clinical trial has tested BPC-157 + TB-500 together. Every dose range below is community-derived from individual-compound research. Numbers are reported as research planning context, not a dosing recommendation.
Wolverine Stack Dosing Guide
Choose the vial format you are using to see the matching schedule and math.
Pre-blended VialSeparate Vials
Convenience-first format. Most common is a 20 mg total vial containing 10 mg BPC-157 + 10 mg TB-500, reconstituted with 2.0 mL BAC water and dosed daily.
Weekly exposure (5–7 days/week)
Independent-control format. Best when BPC-157 and TB-500 doses need to be adjusted on different schedules — most often daily BPC-157 with twice-weekly TB-500 loading.
Cycle structure
These supply estimates assume a pre-blended 20 mg Wolverine vial containing 10 mg BPC-157 plus 10 mg TB-500. The planning dose is 1.0 mg total blend daily (0.5 mg of each compound), so one vial covers about 20 daily draws. Before checkout, compare current peptide discount codes for eligible research suppliers.
Recommended USA Supply
Use discount code PEPPAL at eligible peptide supplier checkouts.
Verified SupplierVerified Supplier
Blood TestAt-Home Blood Test
Injection Supplies
Syringes
Insulin syringes.Buy
Swabs
Sterile alcohol pads.Buy
Peptide Fridge
Lockable fridge.Buy
Peptide Case
Travel case.Buy
TSA Travel Case
Cooled travel case.Buy
Disclosure: supply links may earn PDP a commission at no cost to you.
Pre-blended Wolverine Vials (20 mg total, 1:1)
One 20 mg blend vial contains 10 mg BPC-157 plus 10 mg TB-500. At 1.0 mg total blend per day, each vial covers about 20 daily draws.
Insulin Syringes (U-100, 0.3 mL or 0.5 mL)
One syringe per daily pre-blended injection.
Bacteriostatic Water
Use 2 mL BAC water per pre-blended 20 mg vial.
Round up for priming losses, dropped syringes, damaged swabs, and cycle adjustments. Separate-vial protocols require separate math because injection count and vial coverage change.
Both formats deliver the same two compounds. The choice changes how much control there is over each compound's dose and schedule, and how much injection-site management is needed.
The featured math assumes a pre-blended 20 mg vial containing 10 mg BPC-157 plus 10 mg TB-500. Separate-vial planning can still use 10 mg of each compound, but those vials must be tracked independently. The PepPal reconstitution calculator handles unit math for any vial size.
Reconstitution by Format
Pick the vial format to see the matching math.
Pre-blended VialSeparate Vials
One 20 mg blend vial reconstituted with 2.0 mL BAC water.
Reconstitute BPC-157 and TB-500 independently.
Standard reconstitution steps
1. Allow lyophilized peptide to reach room temperature. 2. Wipe both vial stoppers (peptide and BAC water) with alcohol swabs. 3. Draw the planned volume of BAC water into a sterile syringe. 4. Inject the BAC water against the inside wall of the peptide vial — slowly, never directly onto the powder. 5. Swirl gently until fully dissolved; do not shake. 6. Verify the solution is clear (TB-500 may appear very faintly tinted). 7. Refrigerate (35.6–46.4°F / 2–8°C) and use within the supplier's stated beyond-use window.
Calculator
This Wolverine Stack dosage chart summarizes the common pre-blended 20 mg vial schedule, including the 1:1 BPC-157 and TB-500 ratio, the 2 mL reconstitution setup, and the daily reference dose range. Wolverine Stack dosage chart showing the common 1:1 pre-blended vial setup, 2 mL reconstitution math, and daily reference dose range used on this page.
The stack rationale is mechanistic complementarity. BPC-157 and TB-500 both promote tissue repair, but through largely non-overlapping pathways. Pairing them is hypothesized — not proven — to give broader coverage than either alone.
BPC-157: local repair signaling
BPC-157 is a 15-amino-acid synthetic peptide derived from a sequence found in human gastric juice. Animal-model evidence consistently shows local effects: angiogenesis at the injury site (VEGF upregulation), growth-factor signaling (EGF, FGF), nitric oxide pathway modulation, and accelerated tendon-to-bone interface healing in rat Achilles transection studies.
TB-500: systemic cell migration
TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino-acid actin-binding protein. The parent molecule has Phase 2 human data in cardiac and ocular contexts. Mechanistically, it acts systemically: it sequesters G-actin, promotes endothelial cell migration in scratch-wound assays, and has shown progenitor-cell mobilization signals in preclinical cardiac models.
Where they overlap and where they don't
Synergy is theoretical
No controlled study has tested whether the BPC-157 + TB-500 combination outperforms either compound alone. The rationale is mechanistic, not empirical.
There is no published human safety data for the Wolverine Stack as a combination. Compound-level data is summarized below, separated from theoretical and quality-control concerns.
Compound-level reported effects
BPC-157. Animal studies have reported low acute toxicity. The Vasireddi et al. 2025 systematic review notes the most-cited human exposure as a small open-label knee-pain case series in which 7 of 12 subjects reported pain relief lasting more than 6 months after one intra-articular BPC-157 injection; no serious adverse events were reported. There is no published RCT and no long-term human safety data.
TB-500 (Thymosin Beta-4 fragment). Phase 2 human trials of full-length Thymosin Beta-4 in pressure ulcers and venous stasis ulcers reported no significant adverse events distinguishable from placebo. The TB-500 fragment specifically has not completed a published RCT. Anecdotal reports include mild lethargy or head-pressure during loading phases, but these are not RCT-verified.
Theoretical and stack-level concerns
Both compounds promote angiogenesis, which is the intended mechanism for repair but is also a relevant pathway in tumor growth. A 2003 J Natl Cancer Inst paper by Cha et al. reported that Thymosin Beta-4 expression increased lung-tumor metastasis in a B16-F10 mouse model. The translational meaning for an exogenous TB-500 fragment in humans is unknown, but it is the most-cited theoretical risk in clinician reviews of this stack and is one reason researchers exclude individuals with active or undiagnosed cancer from any informal protocol.
Injection-site and quality-control risk
Reported injection-site issues include redness, mild swelling, transient bruising, and occasional sterile abscess. Most are attributable to technique rather than the peptide. Quality control is the larger practical risk. Independent third-party testing (e.g., Finnrick reports referenced on PepPal supplier pages) has shown variable purity, residual solvents, and endotoxin contamination across grey-market suppliers. Use COA-verified sources.
Sport and competition
Both BPC-157 and TB-500 are prohibited under WADA's S0 Unapproved Substances category, in and out of competition. Athletes subject to WADA, USADA, or any sport-governing-body testing program should not assume a clearance window — the substances are detectable and prohibited regardless of timing.
There is no direct clinical evidence for the Wolverine Stack as a combination. No published trial — preclinical or human — has tested BPC-157 + TB-500 together. All clinical context comes from compound-level research.
BPC-157 evidence
The Vasireddi et al. 2025 systematic review in HSS Journal screened the full BPC-157 musculoskeletal literature through June 2024 and found a large preclinical base — tendon, ligament, muscle, bone, and nerve injury models — but only one published human exposure dataset, the small open-label knee-pain case series. Foundational tendon-bone work includes Krivic et al. 2006 (Achilles detachment in rat, J Orthop Res) and Chang et al. 2011 (tendon outgrowth and migration, J Appl Physiol). Wound-healing and gut work is reviewed in Seiwerth et al. 2021 (Front Vet Sci).
TB-500 / Thymosin Beta-4 evidence
Most TB-500 mechanism work is on the parent molecule Thymosin Beta-4. Foundational studies include Malinda et al. 1997 (FASEB J) showing endothelial cell migration in scratch-wound assays, and Smart et al. 2007 (Angiogenesis) reviewing angiogenic mechanism. The Tβ4 parent molecule has Phase 2 trial data in pressure-ulcer and venous-ulcer indications. The TB-500 fragment specifically has not completed a published RCT.
What this means for the stack
Compound-level evidence does not validate the combination. A coherent mechanistic rationale is not the same as demonstrated synergy, and animal-model effect sizes do not translate cleanly to human dosing. Treat any community-derived Wolverine schedule as a research-planning structure, not as evidence of effect.
Neither BPC-157 nor TB-500 is FDA-approved as of June 2026. Both compounds were on the FDA's 503A Category 2 list — substances raising significant safety concerns and effectively blocked from compounding pharmacies — until April 22, 2026.
April 22, 2026: Removed from Category 2
On April 15, 2026, the FDA published a 503A category revision removing 12 peptides from Category 2 effective seven calendar days later (April 22). BPC-157 and TB-500 were both included. The removal happened because the original nominators voluntarily withdrew their nominations — it is not an FDA determination that these compounds are safe or approved for compounding.
July 23, 2026: Pharmacy Compounding Advisory Committee meeting
The FDA has scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23, 2026 to evaluate BPC-157 and TB-500 (free base and acetate forms), along with KPV and MOTs-C. PCAC will discuss inclusion on the 503A Bulks List. A vote at PCAC is a recommendation to FDA, not a final determination — a final 503A bulks-list decision typically follows weeks-to-months later.
What this means for access
Until PCAC recommends and FDA acts, neither compound is approved for compounding under 503A as a Category 1 substance. Research-chemical channels remain unregulated; compounding pharmacies may not yet legally compound these substances without further FDA action. WADA's S0 prohibition is unaffected by the FDA timeline.
Status changes
Regulatory status as written reflects June 2026. Outcomes from the July 23, 2026 PCAC meeting will materially change this section. Always verify the current 503A list at the FDA's bulk drug substances page.
Related research protocols on PDP that come up alongside Wolverine stack planning:
BPC-157
BPC-157 is the daily tissue-repair component in the Wolverine stack.
TB-500
TB-500 is the longer-interval tissue-repair component in the Wolverine stack.
GLOW Stack
The GLOW Stack adds GHK-Cu to the BPC-157 + TB-500 base.
KLOW Stack
The KLOW Stack adds KPV and GHK-Cu to the Wolverine base.
Retatrutide
The Retatrutide protocol is the better reference when the question shifts from repair-focused stacks to weight and metabolic research.
Stacks Index
The Stacks Index lists the broader PDP stack library.
This stack is usually discussed around tissue repair and connective-tissue stress, but labs may not capture local tendon, ligament, or joint response. Monitoring is mainly a broad safety screen plus inflammation context when symptoms suggest it.
At-home blood test option
Easy at home option to monitor core metrics during research cycles.
Blood TestAt-Home Blood Test
SiPhox Health
SiPhox Health At-Home Blood Test
Monitoring made simple.View Blood Test
Partner link: PDP may earn a commission at no cost to you.
Simple timing framework
Baseline
Discuss baseline labs before starting, especially with autoimmune disease, infection risk, cancer history, liver or kidney issues, anticoagulant use, or a recent major injury.
Follow-up
Repeat broad markers after 6-12 weeks if the protocol continues, symptoms change, or there are concerns about inflammation, infection, bruising, swelling, or recovery quality.
Longer term
For longer or repeated cycles, review trends every 3-6 months with a clinician because long-term human safety data are limited.
How to interpret the labs
BPC-157 and TB-500 are not FDA-approved drugs, and human monitoring standards are not established. Normal labs do not prove that a tendon, ligament, muscle, or joint is healing correctly. Imaging, physical exam findings, pain pattern, strength, range of motion, and function may matter more than bloodwork for local injuries. Medication review is relevant with anticoagulants, immune-modulating drugs, cancer history, or planned procedures.
Do not wait for routine labs
Rapidly worsening swelling, warmth, redness, fever, or drainage near an injury or injection site needs medical review. New chest pain, shortness of breath, one-sided leg swelling, or fainting should be treated as urgent symptoms. Unusual bruising, bleeding, or severe allergic symptoms should not wait for routine lab follow-up. A sudden loss of strength, deformity, or inability to bear weight may need imaging or urgent injury evaluation.
FAQ
Q1: What is the Wolverine Stack?
The Wolverine Stack is a community shorthand for pairing two research peptides — BPC-157 and TB-500 — into one tissue-repair-focused protocol. It is not an FDA-approved treatment and not a clinical designation. The name comes from the comic-book character known for fast healing.
Q2: What is the typical Wolverine Stack dosage?
Two community-derived dosing models dominate. Pre-blended vial: 0.5–2.0 mg total of a 1:1 BPC-157 + TB-500 blend daily for 6–12 weeks. Separate vials: BPC-157 250–500 mcg daily plus TB-500 2–5 mg twice weekly during loading, with a tapered 8–12 week cycle. These are research-planning structures, not dosing recommendations.
Q3: What is the BPC-157 + TB-500 blend dosage chart?
From a 20 mg pre-blended vial reconstituted with 2.0 mL BAC water (10 mg/mL total, 5 mg/mL each compound): 5 units delivers 250 mcg of each, 10 units delivers 500 mcg of each, 15 units delivers 750 mcg of each, and 20 units delivers 1.0 mg of each compound. Use the PepPal calculator for other vial sizes.
Q4: Should I use a pre-blended vial or separate vials?
Pre-blended is simpler — one vial, one daily injection, locked 1:1 ratio. Separate vials let BPC-157 and TB-500 run on independent schedules (most often daily BPC-157 + twice-weekly TB-500 loading) and allow independent dose tuning. Both formats deliver the same compounds; the trade-off is convenience versus control.
Q5: What are the Wolverine Stack side effects?
There is no published human safety dataset for the combination. Compound-level reports from animal studies and small human exposure data describe low acute toxicity; the most common reported issue is injection-site reaction (redness, mild swelling, transient bruising). The most-cited theoretical concern is angiogenesis: both compounds promote new blood vessel formation, which is the intended repair mechanism but also a pathway relevant to tumor growth.
Q6: Is BPC-157 dangerous?
Animal studies and a small open-label human knee-pain case series (Vasireddi et al. 2025 systematic review, HSS Journal) reported no serious adverse events. There is no published long-term human safety data, no completed RCT, and the most-cited theoretical concern remains angiogenesis in the context of undiagnosed cancer. Quality of unregulated supply is also a real, separate risk.
Q7: Why is BPC-157 banned?
BPC-157 was prohibited under WADA's S0 Unapproved Substances category in 2022, restricting use in competition and training. The FDA placed BPC-157 in 503A Category 2 in 2023, which blocked compounding pharmacies from preparing it. On April 22, 2026, BPC-157 was removed from Category 2 because the original nominator withdrew. The FDA's PCAC meeting on July 23, 2026 will evaluate BPC-157 (free base and acetate) for inclusion on the 503A Bulks List.
Q8: Are BPC-157 and TB-500 FDA-approved?
No. As of June 2026, neither compound is FDA-approved. Both were removed from FDA 503A Category 2 on April 22, 2026, but neither is on Category 1 either. PCAC will evaluate both compounds on July 23, 2026, after which FDA will issue a 503A bulks-list determination. Both remain WADA-prohibited.
Q9: How long is a typical Wolverine Stack cycle?
Most community-derived protocols run 6–12 weeks total. A common separate-vial structure is 4 weeks of loading followed by 4–8 weeks of maintenance dosing. Pre-blended protocols often run a steady daily dose for the full cycle without a distinct loading phase. Off-cycle gaps of 2–4 weeks are commonly described but not formalized in any published trial.
Q10: What supplies do I need for a Wolverine Stack cycle?
A typical 8-week pre-blended cycle at 1.0 mg total blend daily uses 3 pre-blended 20 mg vials, 56 U-100 insulin syringes, one 10 mL bacteriostatic water bottle, and 112 alcohol swabs. Cycle-by-cycle math is in the supplies section above.
Q11: Is there any direct evidence the Wolverine Stack works better than either peptide alone?
No published trial — preclinical or human — has tested the combination. The synergy argument is mechanistic, based on non-overlapping pathways for local repair (BPC-157) and systemic cell migration (TB-500). Compound-level evidence does not validate the combination.
Q12: Is this medical advice?
No. This page is an educational research reference. It is not a treatment plan, not a recommendation to use these compounds, and not a substitute for evaluation by a qualified clinician.
Sources & Research
1. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal (2025) 2. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research (2006) 3. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology (2011) 4. Seiwerth S, Milavic M, Vukojevic J, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Veterinary Science (PMC) (2021) 5. Sikiric P, Seiwerth S, Rucman R, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals (MDPI) (2025) 6. Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB Journal (1997) 7. Smart N, Risau W, Stanier P, Riley PR. Thymosin beta-4 and angiogenesis: modes of action and therapeutic potential. Angiogenesis (2007) 8. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mechanisms of Ageing and Development (PubMed) (2004) 9. Xue B, Robinson RC. Progress on the Function and Application of Thymosin β4. Frontiers in Endocrinology (PMC) (2022) 10. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. Journal of the National Cancer Institute (2003) 11. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee — BPC-157, KPV, TB-500, and MOTs-C bulk drug substances. FDA.gov (2026) 12. World Anti-Doping Agency. 2025 World Anti-Doping Code International Standard Prohibited List — Section S0 (Unapproved Substances). WADA (2025)
Related Dosing Protocols
BPC-157 ProtocolTB-500 ProtocolGLOW StackKLOW StackStacks Index
Written by Garret Grant
Founder & Lead Researcher · B.S. Civil Engineering, UCLA
Last updated: June 2026
Human-researched and AI-assisted with full editorial review. I verify sources, protocol interpretation, and final judgments personally. See methodology.
Share this page